1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
February 18, 1999
Date of Report (Date of earliest event reported)
OSI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-15190 13-3159796
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
106 CHARLES LINDBERGH BOULEVARD
UNIONDALE, NY 11553
(Address of principal executive offices)
(516) 222-0023
(Registrant's telephone number, including area code)
2
ITEM 7. EXHIBITS
- -----------------------------------------------------------------------------------------------------------------
EXHIBIT NO. DESCRIPTION
- -----------------------------------------------------------------------------------------------------------------
99 Indenture, dated as of January 6, 1999, between OSI Pharmaceuticals, Inc. and The Bank of
New York, as Trustee.
- -----------------------------------------------------------------------------------------------------------------
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: February 18, 1999 OSI PHARMACEUTICALS, INC.
By: /s/ Robert L. Van Nostrand
-----------------------------------------
Name: Robert L. Van Nostrand
Title: Vice President and Chief Financial
Officer, Secretary and Treasurer
4
EXHIBIT INDEX
- -----------------------------------------------------------------------------------------------------------------
EXHIBIT NO. DESCRIPTION
- -----------------------------------------------------------------------------------------------------------------
99 Indenture, dated as of January 6, 1999, between OSI Pharmaceuticals, Inc. and The Bank of
New York, as Trustee.
- -----------------------------------------------------------------------------------------------------------------